;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • APL-130277: Interim pilot trial data

    Cynapsus Therapeutics Inc. (TSX:CTH), Toronto, Ontario Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine, a small molecule …

    Published on 4/21/2014
  • AVL-301: Additional Phase I data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: AVL-301, CO-1686 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Small …

    Published on 4/21/2014
  • BAX 111: Phase III data

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: BAX 111 (RVWF) Business: Hematology Molecular target: von Willebrand factor (vWF) Description: Recombinant human von Willebrand factor (vWF) Indication: …

    Published on 4/21/2014
  • BGB324: Phase Ia data

    BerGenBio A/S, Bergen, Norway Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: BGB324 (formerly R428) Business: Cancer Molecular target: AXL receptor tyrosine kinase (AXL) (UFO) Description…

    Published on 4/21/2014
  • Bitopertin: Phase III discontinued

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Bitopertin (RO4917838) (R1678, RG1678) Business: Neurology …

    Published on 4/21/2014
  • Bitopertin: Phase III discontinued

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Bitopertin (RO4917838) (R1678, RG1678) Business: Neurology …

    Published on 4/21/2014
  • Bitopertin: Phase III discontinued

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Bitopertin (RO4917838) (R1678, RG1678) Business: Neurology …

    Published on 4/21/2014
  • CYT003: Phase IIb discontinued

    Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland Product: CYT003, CYT003-QbG10 Business: Inflammation Molecular target: Toll-like receptor 9 (TLR9) Description: Virus-like particle (VLP) containing an …

    Published on 4/21/2014
  • Darapladib: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Darapladib (SB-480848) Business: Cardiovascular Molecular target: Lipoprotein-associated phospholipase A2 (PLA2G7) (PAFAH) (Lp-PLA2) Description: Small …

    Published on 4/21/2014
  • Esketamine: Phase IIb data

    Auris Medical AG, Basel, Switzerland Product: Esketamine (AM-101) Business: Other Molecular target: NMDA receptor Description: Intratympanicly injected non-competitive antagonist of NMDA receptors Indication: Treat …

    Published on 4/21/2014
  • GEN-003: Additional Phase I/IIa data

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine …

    Published on 4/21/2014
  • GSK2586184: Phase IIa data

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK2586184 (formerly GLPG0778) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) …

    Published on 4/21/2014
  • LX4211 tablet: Phase II data

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Product: LX4211 tablet Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter 1 (SGLT1); Sodium-glucose cotransporter 2 (SGLT2) …

    Published on 4/21/2014
  • OTX015: Interim Phase Ib data

    Oncoethix S.A., Lausanne, Switzerland Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: OTX015, Y-803 Business: Cancer Molecular target: Bromodomain containing 2 (BRD2); Bromodomain containing 3 (BRD3) …

    Published on 4/21/2014
  • Remogliflozin etabonate: Phase IIb data

    BHV Pharma Inc., Research Triangle Park, N.C. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Remogliflozin etabonate (BHV091009, KGT-1681) (formerly GSK189075) Business: Endocrine/Metabolic …

    Published on 4/21/2014
  • Resiniferatoxin: Phase I/II data

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Product: Resiniferatoxin (RTX) Business: Neurology Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1) Description: Non-opiate agonist of …

    Published on 4/21/2014
  • SHACT: Feasibility study data

    Pharmanest AB, Solna, Sweden Product: SHACT Business: Neurology Molecular target: NA Description: Topical 4% formulation of lidocaine Indication: Treat pain associated with hysteroscopies Endpoint: Feasibility of …

    Published on 4/21/2014
  • UX003: Preliminary Phase I/II data

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Product: UX003 (RhGUS) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human glucuronidase beta (rhGUS) Indication: Treat …

    Published on 4/21/2014
  • VAL-083: Additional Phase I/II data

    DelMar Pharmaceuticals Inc. (OTCBB:DMPI), Vancouver, B.C. Guangxi Wuzhou Zhongheng Group Co. Ltd. (Shanghai:600252), Wuzhou, China Product: VAL-083 (DAG for Injection) Business: Cancer Molecular target: DNA Description:…

    Published on 4/21/2014
  • 19-28z CAR T cells: Phase I halted

    Juno Therapeutics Inc., Seattle, Wash. Product: 19-28z CAR T cells Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 …

    Published on 4/14/2014
  • AG-221: Preliminary Phase I data

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-221 Business: Cancer Molecular target: Isocitrate dehydrogenase 2 (IDH2) Description: Inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) …

    Published on 4/14/2014
  • Ampligen rintatolimod: Additional Phase III data

    Hemispherx Biopharma Inc. (NYSE-M:HEB), Philadelphia, Pa. Product: Ampligen rintatolimod Business: Neurology Molecular target: 2',5'-oligoadenylate synthetase 1, 40-46kDa (OAS1); Toll-like receptor 3 (TLR3) Description:…

    Published on 4/14/2014
  • AP301: Phase IIa data

    Apeptico Forschung und Entwicklung GmbH, Vienna, Austria Product: AP301 Business: Pulmonary Molecular target: Epithelial sodium channel (ENaC) Description: Human tumor necrosis factor (TNF) alpha-derived peptide that …

    Published on 4/14/2014
  • Aripiprazole lauroxil: Phase III data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: Aripiprazole lauroxil (ALKS 9072, ALKS 9070) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT) receptor Description: Injectable, extended-…

    Published on 4/14/2014
  • Astuprotimut-R: Phase III discontinued

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Astuprotimut-R (MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI)) (GSK1572932A) Business: Cancer Molecular target: Melanoma-associated antigen A3 (…

    Published on 4/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993